The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Targeted anticancer therapy: Overexpressed receptors and nanotechnology
Abstract
Targeted delivery of anticancer drugs to cancer cells and tissues is a promising field due to its potential to spare unaffected cells and tissues, but it has been a major challenge to achieve success in these therapeutic approaches. Several innovative approaches to targeted drug delivery have been devised based on available knowledge in cancer biology and on technological advancements. To achieve the desired selectivity of drug delivery, nanotechnology has enabled researchers to design nanoparticles (NPs) to incorporate anticancer drugs and act as nanocarriers. Recently, many receptor molecules known to be overexpressed in cancer have been explored as docking sites for the targeting of anticancer drugs. In principle, anticancer drugs can be concentrated specifically in cancer cells and tissues by conjugating drug-containing nanocarriers with ligands against these receptors. Several mechanisms can be employed to induce triggered drug release in response to either endogenous trigger or exogenous trigger so that the anticancer drug is only released upon reaching and preferentially accumulating in the tumor tissue. This review focuses on overexpressed receptors exploited in targeting drugs to cancerous tissues and the tumor microenvironment. We briefly evaluate the structure and function of these receptor molecules, emphasizing the elegant mechanisms by which certain characteristics of cancer can be exploited in cancer treatment. After this discussion of receptors, we review their respective ligands and then the anticancer drugs delivered by nanotechnology in preclinical models of cancer. Ligand-functionalized nanocarriers have delivered significantly higher amounts of anticancer drugs in many in vitro and in vivo models of cancer compared to cancer models lacking such receptors or drug carrying nanocarriers devoid of ligand. This increased concentration of anticancer drug in the tumor site enabled by nanotechnology could have a major impact on the efficiency of cancer treatment while reducing systemic side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Wiederschain, G. Y. (2009) · Biochemistry (Moscow) · doi:10.1134/s0006297909090156 · Cited by 4,083
Integrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Molecular classification of cutaneous malignant melanoma by gene expression profiling
Bittner, M., Meltzer, P., Chen, Y., Jiang, Y., Seftor, E., Hendrix, M., Radmacher, M., Simon, R., Yakhini, Z., Ben-Dor, A., et al. (2000) · Nature · doi:10.1038/35020115 · Cited by 1,990
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846
Hayashi, T., & Su, T.-P. (2007) · Cell · doi:10.1016/j.cell.2007.08.036 · Cited by 1,826
Humphries, J. D., Byron, A., & Humphries, M. J. (2006) · Journal of Cell Science · doi:10.1242/jcs.03098 · Cited by 1,708
Integrin-regulated FAK–Src signaling in normal and cancer cells
Mitra, S. K., & Schlaepfer, D. D. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.011 · Cited by 1,590
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Targeted drug delivery via the folate receptor
Sudimack, J., & Lee, R. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00062-9 · Cited by 1,474
Integrin signalling during tumour progression
Guo, W., & Giancotti, F. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1490 · Cited by 1,471
Saito, G., Swanson, J. A., & Lee, K.-D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00179-5 · Cited by 1,407
Csordás, G., Renken, C., Várnai, P., Walter, L., Weaver, D., Buttle, K. F., Balla, T., Mannella, C. A., & Hajnóczky, G. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200604016 · Cited by 1,373
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Mammalian G Proteins and Their Cell Type Specific Functions
Wettschureck, N., & Offermanns, S. (2005) · Physiological Reviews · doi:10.1152/physrev.00003.2005 · Cited by 1,166
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Girard, O. M., Hanahan, D., Mattrey, R. F., & Ruoslahti, E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.013 · Cited by 1,136
Pytela, R., Pierschbacher, M. D., & Ruoslahti, E. (1985) · Cell · doi:10.1016/0092-8674(85)90322-8 · Cited by 1,101
Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway
Qian, Z. M., Li, H., Sun, H., & Ho, K. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.561 · Cited by 1,019
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Berrier, A. L., & Yamada, K. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21237 · Cited by 957
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Recent progress in tumor pH targeting nanotechnology
Lee, E. S., Gao, Z., & Bae, Y. H. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.003 · Cited by 866
Sigma receptors: biology and function.
Walker, J. M., Bowen, W. D., Walker, F. O., Matsumoto, R. R., De Costa, B., & Rice, K. C. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00047-x · Cited by 825
Protein-glycan interactions in the control of innate and adaptive immune responses
van Kooyk, Y., & Rabinovich, G. A. (2008) · Nature Immunology · doi:10.1038/ni.f.203 · Cited by 807
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Daniels, T. R., Bernabeu, E., Rodríguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., Holler, E., Ljubimova, J. Y., Helguera, G., & Penichet, M. L. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.07.016 · Cited by 807
Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface
Csordás, G., Várnai, P., Golenár, T., Roy, S., Purkins, G., Schneider, T. G., Balla, T., & Hajnóczky, G. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.029 · Cited by 750
Structural basis for fibroblast growth factor receptor activation
Mohammadi, M., Olsen, S. K., & Ibrahimi, O. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.008 · Cited by 735
Levin, E. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330607 · Cited by 711
Structural basis for molecular recognition of folic acid by folate receptors
Chen, C., Ke, J., Zhou, X. E., Yi, W., Brunzelle, J. S., Li, J., Yong, E.-L., Xu, H. E., & Melcher, K. (2013) · Nature · doi:10.1038/nature12327 · Cited by 694
The pharmacology of sigma-1 receptors.
Maurice, T., & Su, T.-P. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.001 · Cited by 654
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
The deaf and the dumb: the biology of ErbB-2 and ErbB-3
Citri, A. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00101-5 · Cited by 595
Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591
The endothelin axis: emerging role in cancer
Nelson, J., Bagnato, A., Battistini, B., & Nisen, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc990 · Cited by 564
Leamon, C. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.01.008 · Cited by 558
Steroid Binding at σ Receptors Suggests a Link Between Endocrine, Nervous, and Immune Systems
Su, T.-P., London, E. D., & Jaffe, J. H. (1988) · Science · doi:10.1126/science.2832949 · Cited by 546
Jensen, R. T., Battey, J. F., Spindel, E. R., & Benya, R. V. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07108 · Cited by 536
The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Signaling by Myeloid C-Type Lectin Receptors in Immunity and Homeostasis
Sancho, D., & Reis e Sousa, C. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101352 · Cited by 520
Kelemen, L. E. (2006) · International Journal of Cancer · doi:10.1002/ijc.21712 · Cited by 509
Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis
Murphy, E. A., Majeti, B. K., Barnes, L. A., Makale, M., Weis, S. M., Lutu-Fuga, K., Wrasidlo, W., & Cheresh, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803728105 · Cited by 455
Role of Integrins in Cancer: Survey of Expression Patterns
Mizejewski, G. J. (1999) · Proceedings of the Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-122.x · Cited by 451
Yoo, H. S., & Park, T. G. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.017 · Cited by 444
Su, T. P. (1982) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33330-6 · Cited by 436
ErbB receptors: new insights on mechanisms and biology
LINGGI, B., & CARPENTER, G. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.008 · Cited by 377
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Cobos, E., Entrena, J., Nieto, F., Cendan, C., & Pozo, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386113 · Cited by 376
Zhan, C., Gu, B., Xie, C., Li, J., Liu, Y., & Lu, W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.12.020 · Cited by 366
Targeted drug delivery via folate receptors
Zhao, X., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358
Chen, S., Zhao, X., Chen, J., Chen, J., Kuznetsova, L., Wong, S. S., & Ojima, I. (2010) · Bioconjugate Chemistry · doi:10.1021/bc9005656 · Cited by 357
Heo, D. N., Yang, D. H., Moon, H.-J., Lee, J. B., Bae, M. S., Lee, S. C., Lee, W. J., Sun, I.-C., & Kwon, I. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.064 · Cited by 357
Multifunctional Micellar Nanomedicine for Cancer Therapy
Blanco, E., Kessinger, C. W., Sumer, B. D., & Gao, J. (2009) · Experimental Biology and Medicine · doi:10.3181/0808-mr-250 · Cited by 332
Regulating ankyrin dynamics: Roles of sigma-1 receptors
Hayashi, T., & Su, T.-P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.491 · Cited by 329
Prabaharan, M., Grailer, J. J., Pilla, S., Steeber, D. A., & Gong, S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.02.011 · Cited by 317
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment
Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S., Liu, J., Wei, T., Cao, W., Zou, G., & Liang, X.-J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.058 · Cited by 315
Roles of Fibroblast Growth Factor Receptors in Carcinogenesis
Haugsten, E. M., Wiedlocha, A., Olsnes, S., & Wesche, J. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0168 · Cited by 315
Powell, L. D., & Varki, A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14243 · Cited by 312
Anticancer Antifolates: Current Status and Future Directions
McGuire, J. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033453712 · Cited by 305
Light‐Regulated Release of DNA and Its Delivery to Nuclei by Means of Photolabile Gold Nanoparticles
Han, G., You, C., Kim, B., Turingan, R. S., Forbes, N. S., Martin, C. T., & Rotello, V. M. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600214 · Cited by 296
Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB)
Ulbrich, K., Knobloch, T., & Kreuter, J. (2011) · Journal of Drug Targeting · doi:10.3109/10611861003734001 · Cited by 259
Chen, X., Plasencia, C., Hou, Y., & Neamati, N. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049165z · Cited by 256
Neuropilins in neoplasms: Expression, regulation, and function
Bielenberg, D. R., Pettaway, C. A., Takashima, S., & Klagsbrun, M. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.024 · Cited by 255
Targeting C-type lectin receptors with multivalent carbohydrate ligands
Lepenies, B., Lee, J., & Sonkaria, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.05.007 · Cited by 251
Blessing, T., Kursa, M., Holzhauser, R., Kircheis, R., & Wagner, E. (2001) · Bioconjugate Chemistry · doi:10.1021/bc0001488 · Cited by 245
Crawford, K. W., & Bowen, W. D. (2002) · PubMed · Cited by 240
Pan, J., & Feng, S.-S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.10.039 · Cited by 238
Sigma receptors: biology and therapeutic potential
Guitart, X., Codony, X., & Monroy, X. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1920-9 · Cited by 234
Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J., & Low, P. S. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.003723 · Cited by 220
Wei, H., Zhang, X., Cheng, C., Cheng, S.-X., & Zhuo, R.-X. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.08.030 · Cited by 217
Gonzalez, N., Moody, T. W., Igarashi, H., Ito, T., & Jensen, R. T. (2008) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3282f3709b · Cited by 208
De-regulated FGF receptors as therapeutic targets in cancer
Knights, V., & Cook, S. J. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.001 · Cited by 196
Habeshaw, J. A., Lister, T. A., Stansfeld, A. G., & Greaves, M. F. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92191-8 · Cited by 190
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles
Pan, J., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.02.020 · Cited by 187 · cited 1×
“These results further showed that the folate decoration could promote significantly higher delivery of thedrug into the corresponding cancer cells, enhancing therapeutic effect [92].”
BackgroundRecht, L., Torres, C. O., Smith, T. W., Raso, V., & Griffin, T. W. (1990) · Journal of Neurosurgery · doi:10.3171/jns.1990.72.6.0941 · Cited by 185
Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes
Smith, C. J., Volkert, W. A., & Hoffman, T. J. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.05.005 · Cited by 181
Transferrin As A Targeting Ligand for Liposomes and Anticancer Drugs
Singh, M. (1999) · Current Pharmaceutical Design · doi:10.2174/138161280506230110111312 · Cited by 181
Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Cai, W., Niu, G., & Chen, X. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404308 · Cited by 178
Applications of synthetic carbohydrates to chemical biology
Lepenies, B., Yin, J., & Seeberger, P. H. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.016 · Cited by 177
Pal, A., Fontanilla, D., Gopalakrishnan, A., Chae, Y.-K., Markley, J. L., & Ruoho, A. E. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.030 · Cited by 177
Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate
Reddy, J. A., Dorton, R., Westrick, E., Dawson, A., Smith, T., Xu, L.-C., Vetzel, M., Kleindl, P., Vlahov, I. R., & Leamon, C. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0033 · Cited by 176
Cell-specific delivery of genes with glycosylated carriers
HASHIDA, M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00209-5 · Cited by 171
Sigma receptors in post-mortem human brains.
Weissman, A. D., Su, T. P., Hedreen, J. C., & London, E. D. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20023-4 · Cited by 168
EGF Receptor-Targeted Nanocarriers for Enhanced Cancer Treatment
Master, А. M., & Gupta, A. S. (2012) · Nanomedicine · doi:10.2217/nnm.12.160 · Cited by 161
HER2-Positive Breast Cancer: Current and Future Treatment Strategies
Engel, R. H., & Kaklamani, V. (2007) · Drugs · doi:10.2165/00003495-200767090-00006 · Cited by 157
Wang, F., Kan, M., Yan, G.-C., Xu, J.-M., & Mckeehan, W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.10231 · Cited by 157
Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting
Chen, K., Xie, J., Xu, H., Behera, D., Michalski, M. H., Biswal, S., Wang, A., & Chen, X. S. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.045 · Cited by 157
Mansoori, G. A., Brandenburg, K. S., & Shakeri‐Zadeh, A. (2010) · Cancers · doi:10.3390/cancers2041911 · Cited by 157
Song, S., Liu, D., Peng, J., Deng, H., Guo, Y., Xu, L. X., Miller, A. D., & Xu, Y. (2009) · The FASEB Journal · doi:10.1096/fj.08-117002 · Cited by 157
Folic Acid Conjugates for Nuclear Imaging of Folate Receptor–Positive Cancer
Müller, C., & Schibli, R. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076018 · Cited by 156
Ultrasound-triggered drug targeting of tumors in vitro and in vivo
Rapoport, N. Y., Christensen, D. A., Fain, H. D., Barrows, L. R., & Gao, Z. (2004) · Ultrasonics · doi:10.1016/j.ultras.2004.01.087 · Cited by 150
Tumor-Targeting Nanoimmunoliposome Complex for Short Interfering RNA Delivery
Pirollo, K. F., Zon, G., Rait, A. S., Zhou, Q., Yu, W. H., Hogrefe, R. I., & Chang, E. H. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.117 · Cited by 147
Mitochondria and Endoplasmic Reticulum: The Lethal Interorganelle Cross-Talk
Walter, L., & Hajnóczky, G. (2005) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-005-6600-x · Cited by 145
Role of Sigma-1 Receptor C-terminal Segment in Inositol 1,4,5-Trisphosphate Receptor Activation
Wu, Z., & Bowen, W. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802099200 · Cited by 137
Kashiwagi, H., McDunn, J. E., Simon, P. O., Goedegebuure, P. S., Xu, J., Jones, L. A., Chang, K. C., Johnston, F. M., Trinkaus, K. M., Hotchkiss, R. S., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-48 · Cited by 132
Jiang, X., Sha, X., Xin, H., Chen, L., Gao, X., Wang, X., Law, K., Gu, J., Chen, Y., Jiang, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.055 · Cited by 124
Somatostatin Receptor-Targeted Anti-Cancer Therapy
Sun, L., & Coy, D. H. (2010) · Current Drug Delivery · doi:10.2174/156720111793663633 · Cited by 123
Zeng, C., Vangveravong, S., Xu, J., Chang, K. C., Hotchkiss, R. S., Wheeler, K. T., Shen, D., Zhuang, Z., Kung, H. F., & Mach, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3803 · Cited by 119
Gabizón, A., Tzemach, D., Gorin, J., Mak, L., Amitay, Y., Shmeeda, H., & Zalipsky, S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1132-4 · Cited by 116
Camp, E. R., Wang, C., Little, E. C., Watson, P. M., Pirollo, K. F., Rait, A. S., Cole, D. J., Chang, E. H., & Watson, D. K. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.9 · Cited by 115
Inoue, T., Cavanaugh, P. G., Steck, P. A., Brünner, N., & Nicolson, G. L. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041560128 · Cited by 114
Increased tumor cell dissemination and cellular senescence in the absence of β1‐integrin function
Kren, A., Baeriswyl, V., Lehembre, F., Wunderlin, C., Strittmatter, K., Antoniadis, H., Fässler, R., Cavallaro, U., & Christofori, G. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601738 · Cited by 113
Dufès, C., Al Robaian, M., & Somani, S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.21 · Cited by 110
Cummings, J., & McArdle, C. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.141 · Cited by 109
Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate
Leamon, C. P., Reddy, J. A., Vlahov, I. R., Westrick, E. M., Dawson, A., Dorton, R., Vetzel, M., Santhapuram, H. K. R., & Wang, Y. (2007) · Molecular Pharmaceutics · doi:10.1021/mp070049c · Cited by 109
Parry, J. J., Kelly, T. S., Andrews, R., & Rogers, B. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603788 · Cited by 106
Shia, J., Klimstra, D. S., Nitzkorski, J. R., Low, P. S., Gonen, M., Landmann, R., Weiser, M. R., Franklin, W. A., Prendergast, F. G., Murphy, L., et al. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.09.013 · Cited by 106
Wang, J., Liu, W., Tu, Q., Wang, J., Song, N., Zhang, Y., Nie, N., & Wang, J. (2010) · Biomacromolecules · doi:10.1021/bm101206g · Cited by 106
Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma Ligands
van Waarde, A., Rybczynska, A. A., Ramakrishnan, N. K., Ishiwata, K., Elsinga, P. H., & Dierckx, R. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210793563365 · Cited by 103
Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells.
Bagnato, A., Tecce, R., Moretti, C., Castro, V. D., Spergel, D. J., & Catt, K. J. (1995) · PubMed · Cited by 103
Zhang, J., Wu, J., Wang, X., Wang, J., Zhang, X., & Zhang, Q. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1000235 · Cited by 101
Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate.
Matsue, H., Rothberg, K. G., Takashima, A., Kamen, B. A., Anderson, R. G. W., & Lacey, S. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6006 · Cited by 99
Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring
Schlessinger, J., & Lemmon, M. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.013 · Cited by 98
Zhang, X., Chen, J., Zheng, Y., Gao, X., Kang, Y., Liu, J.-C., Cheng, M., Sun, H., & Xu, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4721 · Cited by 98
Transferrin receptor expression by human bladder transitional cell carcinomas
Seymour, G. J., Walsh, M. D., Lavin, M. F., Strutton, G., & Gardiner, R. A. (1987) · Urological Research · doi:10.1007/bf00265663 · Cited by 97
Huo, M., Zou, A., Yao, C., Zhang, Y., Zhou, J., Wang, J., Zhu, Q., Li, J., & Zhang, Q. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.052 · Cited by 97
Sensing of cell death by myeloid C-type lectin receptors
Sancho, D., & Sousa, C. R. E. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.007 · Cited by 95
Xiao, K., Li, Y., Lee, J. S., Gonik, A. M., Dong, T., Fung, G., Sanchez, E., Li, X., Cheng, H. R., Luo, J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3883 · Cited by 94
Roldan, J. O., Ossa, F., & Schnell, J. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.450379 · Cited by 92
The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids
Ramachandran, S., Chu, U. B., Mavlyutov, T. A., Pal, A., Pyne, S., & Ruoho, A. E. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.003 · Cited by 91
Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis
Huang, C., Wu, Y., & Chen, S.-T. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00131-9 · Cited by 88
Yang, D. C., Wang, F., Elliott, R. L., & Head, J. F. (2001) · PubMed · Cited by 87
Jiang, W., Xie, H., Ghoorah, D., Shang, Y., Shi, H., Liu, F., Yang, X., & Xu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037376 · Cited by 86
Seth, P., Ganapathy, M. E., Conway, S. J., Bridges, C. D., Smith, S. B., Casellas, P., & Ganapathy, V. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(01)00117-3 · Cited by 86
Prior, R., Reifenberger, G., & Wechsler, W. (1990) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf01600299 · Cited by 86
Kondo, K., Noguchi, M., Mukai, K., Matsuno, Y., Sato, Y., Shimosato, Y., & Monden, Y. (1990) · CHEST Journal · doi:10.1378/chest.97.6.1367 · Cited by 83
Endogenous carriers and ligands in non-immunogenic site-specific drug delivery
Vyas, S. P., & Sihorkar, V. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00067-3 · Cited by 82
Rd, C., & Schnaar, L. R. (2009) · Europe PMC (PubMed Central) · Cited by 82
Physiology of somatostatin receptors.
Guillermet‐Guibert, J., Lahlou, H., Cordelier, P., Bousquet, C., Pyronnet, S., & Susini, C. (2005) · PubMed · Cited by 81
Bernardes, G. J. L., Kikkeri, R. V., Maglinao, M., Laurino, P., Collot, M., Hong, S. Y., Lepenies, B., & Seeberger, P. H. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00372g · Cited by 81
Deng, Y., Zhou, X., Desmoulin, S. K., Wu, J., Cherian, C., Hou, Z., Matherly, L. H., & Gangjee, A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8011323 · Cited by 81
Hornick, J. R., Xu, J., Vangveravong, S., Tu, Z., Mitchem, J. B., Spitzer, D., Goedegebuure, P. S., Mach, R. H., & Hawkins, W. G. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-298 · Cited by 78
Regulation and signaling of human bombesin receptors and their biological effects
Weber, H. C. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32831cf5aa · Cited by 77
Lin, L., & Liu (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32830 · Cited by 72
Biotin-conjugated block copolymeric nanoparticles as tumor-targeted drug delivery systems
Kim, S. Y., Cho, S. H., Lee, Y. M., & Chu, L. (2007) · Macromolecular Research · doi:10.1007/bf03218945 · Cited by 70
The promise of glycomics, glycan arrays and carbohydrate-based vaccines
Lepenies, B., & Seeberger, P. H. (2010) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923970903292663 · Cited by 68
Riviere, K., Huang, Z. R., Jerger, K., Macaraeg, N., & Szoka, F. C. (2010) · Journal of drug targeting · doi:10.3109/10611861003733953 · Cited by 68
Morelli, G., Accardo, A., Tesauro, D., Cicala, C., Salzano, G., Rosa, G. D., Morisco, A., Aloj, L., Aurilio, M., Μaione, F., et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29242 · Cited by 66
How do Receptors Activate G Proteins?
Oldham, W. M., & Hamm, H. E. (2007) · Advances in protein chemistry · doi:10.1016/s0065-3233(07)74002-0 · Cited by 64
Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome
Xiao, W., Chen, X., Li, Y., Mao, Y.-Q., Wei, Y., & Chen, L. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.018 · Cited by 60
Singh, A., Dilnawaz, F., & Sahoo, S. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026803 · Cited by 59
Taheri, A., Dinarvand, R., Atyabi, F., Ghahremani, M. H., & Ostad, S. N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.016 · Cited by 59
Wei, H., Zhang, X., Chen, W., Cheng, S., & Zhuo, R. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31295 · Cited by 58
An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma
Asundi, J., Reed, C., Arca, J., McCutcheon, K. M., Ferrando, R. E., Clark, S., Luis, E., Tien, J., Firestein, R., & Polakis, P. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2340 · Cited by 58
Kircheis, R., Wightman, L., Kursa, M., Ostermann, E., & Wagner, E. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301748 · Cited by 57
Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy
Heinzle, C. F., Sutterlüty, H., Grusch, M., Grasl‐Kraupp, B., Berger, W., & Marian, B. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.566217 · Cited by 55
Spitzer, D., Simon, P. O., Kashiwagi, H., Xu, J., Zeng, C., Vangveravong, S., Zhou, D., Chang, K. C., McDunn, J. E., Hornick, J. R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1354 · Cited by 53
Wang, J., Lin, L., Parkash, V., Schwartz, P. E., Lauchlan, S. C., & Zheng, W. (2002) · International Journal of Cancer · doi:10.1002/ijc.10848 · Cited by 53
Chirasani, S. R., Marković, D., Synowitz, M., Eichler, S. A., Wiśniewski, P., Kaminska, B., Otto, A., Wanker, E. E., Schäfer, M. K. E., Chiarugi, P., et al. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0414-3 · Cited by 53
Aina, O. H., Mařı́k, J., Gandour‐Edwards, R. F., & Lam, K. S. (2005) · Molecular Imaging · doi:10.2310/7290.2005.05169 · Cited by 52
SV119-gold nanocage conjugates: a new platform for targeting cancer cellsvia sigma-2 receptors
Wang, Y., Xu, J., Xia, X., Yang, M., Vangveravong, S., Chen, J., Mach, R. H., & Younan Xia, A. (2011) · Nanoscale · doi:10.1039/c1nr11469g · Cited by 50
Sun, M., Wang, Y., Shen, J., Xiao, Y., Su, Z., & Ping, Q. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/47/475101 · Cited by 49
Shen, H., Hu, D., Du, J., Wang, X., Liu, Y., Wang, Y., Wei, J., Ma, D., Wang, P., & Li, L. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.035 · Cited by 44
Franko-Tobin, L. G., Mackey, L. V., Huang, W. Y., Song, X., Jin, B., Luo, J., Morris, L. M., Liu, M., Fuselier, J. A., Coy, D. H., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0269 · Cited by 42
Peptide modified nanocarriers for selective targeting of bombesin receptors
Accardo, A., Mansi, R., Morisco, A., Mangiapia, G., Paduano, L., Tesauro, D., Rădulescu, A., Aurilio, M., Aloj, L., Arra, C., et al. (2010) · Molecular BioSystems · doi:10.1039/b923147a · Cited by 41
Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker
Hou, C., Tu, Z., Mach, R. H., Kung, H. F., & Kung, M. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.10.001 · Cited by 39
Yoon, D. J., Kwan, B. H., Chao, F. C., Nicolaides, T. P., Phillips, J. J., Lam, G. Y., Mason, A. B., Weiss, W. A., & Kamei, D. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4311 · Cited by 39
Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands
Hornick, J. R., Spitzer, D., Goedegebuure, P. S., Mach, R. H., & Hawkins, W. G. (2012) · Surgery · doi:10.1016/j.surg.2012.05.014 · Cited by 39
Chen, L., Cai, Wang, W., Wang, W., Qiu, Wen, Duan, Li, Yang, Y., Qian, Z., et al. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s32817 · Cited by 39
Ai, S., Jia, T., Ai, W., Duan, J., Liu, Y., Chen, J., Liu, X., Yang, F., Tian, Y., & Huang, Z. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12055 · Cited by 38
The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells
Hu, C.-Y., Yi, C.-Q., Hao, Z., Cao, S., Li, H., Shao, X., Zhang, J., Qiao, T., & Fan, D. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.8.962 · Cited by 37
σ receptors on NCB-20 hybrid neurotumor cells labeled with (+)[3H]SKF 10,047 and (+)[3H]3-PPP
Largent, B. L., Gundlach, A. L., & Snyder, S. H. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90142-1 · Cited by 35
Otlewski, J., Szlachcic, Pala, Zakrzewska, Jakimowicz, & Wiedlocha (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s36575 · Cited by 34
Li, S., Zhang, Y., Huang, Zhang, Gao, & Gibbs (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s31981 · Cited by 33
Cai, L., Qiu, N., Li, X., Luo, K., Chen, X., Yang, L., He, G., Wei, Y., & Chen, L. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.01.042 · Cited by 33
Pan, W., Han, C., Yue, L., Tai, L., Li, Z., Li, X., Xing, G., Yang, X., & Sun, L. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s43627 · Cited by 33
Mariniello, B., Finco, I., Sartorato, P., Patalano, A., Iacobone, M., Guzzardo, V., Fassina, A., & Mantero, F. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346721 · Cited by 32
Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications
Konishi, I. (2006) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-00009577-200601000-00003 · Cited by 31
Safavy, A., Raisch, K. P., Matusiak, D., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc050224c · Cited by 30
Sclafani, F., Carnaghi, C., Tommaso, L. D., Rodari, M., Destro, A., Rimassa, L., Giordano, L., Chiti, A., Roncalli, M. G., & Santoro, A. (2011) · Tumori Journal · doi:10.1177/030089161109700514 · Cited by 25
Liu, X., Ma, S., Dai, C., Cai, F., Yao, Y., Yang, Y., Feng, M., Deng, K., Li, G., Ma, W., et al. (2013) · Endocrinology · doi:10.1210/en.2012-2128 · Cited by 22
Targeted Toxins for Glioblastoma Multiforme: Pre-Clinical Studies and Clinical Implementation
Candolfi, M., Kroeger, K. M., Xiong, W., Liu, C., Puntel, M., Yagiz, K., Muhammad, A. G., Mineharu, Y., Foulad, D. S., Wibowo, M., et al. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011797378689 · Cited by 18
Cited by
Polymeric nanoparticles for targeted drug delivery system for cancer therapy
Masood, F. (2016) · Materials Science and Engineering: C · doi:10.1016/j.msec.2015.11.067 · Cited by 702
Polymeric nanoparticles: Promising platform for drug delivery
El-Say, K. M., & El-Sawy, H. S. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.06.052 · Cited by 608
Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy
Li, H., Kim, Y., Jung, H., Hyun, J. Y., & Shin, I. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00722c · Cited by 356
Wuttke, S., Lismont, M., Escudero, A., Rungtaweevoranit, B., & Parak, W. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.025 · Cited by 286
Stealth nanoparticles in oncology: Facing the PEG dilemma
Zalba, S., ten Hagen, T. L. M., Burgui, C., & Garrido, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.002 · Cited by 278
Metadata
- Authors
- Akhtar, M. J., Ahamed, M., Alhadlaq, H. A., Alrokayan, S. A., & Kumar, S.
- Venue
- Clinica Chimica Acta
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 436
- Pages
- 78-92
- ISSN
- 0009-8981 (ISSN-L)
- OpenAlex
- W2090691166
- Cited by
- 255
- References
- 180
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.